|
|
|
Insider
Information: |
Eshelman Fredric N |
Relationship: |
10% Owner |
City: |
Wilmington |
State: |
NC |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
8,151,654 |
|
Indirect Shares
|
3,933,809 |
|
|
Direct
Value |
$95,684,563 |
|
|
Indirect Value
|
$13,709,856 |
|
|
Total
Shares |
12,085,463 |
|
|
Total
Value |
$109,394,419 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
7
|
3
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
7
|
3
|
|
|
|
Gain/Loss Ratio : |
-7.0
|
-3.0
|
Percentage
Gain/Loss : |
-45.7%
|
-43.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmaceutical Product Developme... |
PPDI |
Executive Chairman, Di... |
2011-12-05 |
0 |
2011-12-05 |
0 |
Premium* |
|
Furiex Pharmaceuticals, Inc. |
FURX |
Director, 10% Owner |
2014-07-02 |
0 |
2014-07-02 |
0 |
Premium* |
|
Bausch Health Companies Inc |
BHC |
Director |
2017-05-05 |
38,298 |
2016-03-11 |
0 |
Premium* |
|
G1 Therapeutics Inc |
GTHX |
Director, 10% Owner |
2017-11-13 |
250,000 |
2017-11-13 |
3,439,151 |
Premium* |
|
Eyenovia Inc |
EYEN |
Director |
2020-09-11 |
1,292,787 |
2020-09-11 |
319,085 |
Premium* |
|
Liquidia Technologies Inc |
LQDA |
10% Owner |
2020-11-25 |
6,570,569 |
2020-11-25 |
175,573 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
PPDI |
Pharmaceutical Product De... |
officerTitle |
|
2007-03-01 |
4 |
S |
$31.06 |
$1,633,876 |
D/D |
(52,133) |
9,131,827 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
officerTitle |
|
2007-03-01 |
4 |
S |
$31.42 |
$981,403 |
D/D |
(31,200) |
9,100,627 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-03-19 |
4 |
S |
$31.80 |
$9,541 |
D/D |
(300) |
9,017,293 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-03-19 |
4 |
S |
$31.41 |
$2,629,611 |
D/D |
(83,034) |
9,017,593 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-04-02 |
4 |
S |
$33.40 |
$2,799,552 |
D/D |
(83,333) |
8,933,960 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-04-16 |
4 |
S |
$34.05 |
$813,495 |
D/D |
(23,800) |
8,910,160 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-04-16 |
4 |
S |
$34.36 |
$1,203,208 |
D/D |
(34,800) |
8,875,360 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-04-16 |
4 |
S |
$34.69 |
$860,186 |
D/D |
(24,733) |
8,850,627 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-05-01 |
4 |
S |
$35.03 |
$2,229,681 |
D/D |
(63,433) |
8,768,194 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-05-01 |
4 |
S |
$34.46 |
$31,970 |
D/D |
(900) |
8,767,294 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-05-01 |
4 |
S |
$34.63 |
$663,142 |
D/D |
(19,000) |
8,831,627 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-05-14 |
4 |
S |
$33.79 |
$305,160 |
D/D |
(9,000) |
8,683,960 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-05-14 |
4 |
S |
$33.48 |
$2,497,943 |
D/D |
(74,334) |
8,692,960 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-01 |
4 |
S |
$36.91 |
$789,374 |
D/D |
(21,341) |
8,600,827 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-01 |
4 |
S |
$36.39 |
$2,273,094 |
D/D |
(61,792) |
8,622,168 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-01 |
4 |
S |
$37.27 |
$7,454 |
D/D |
(200) |
8,600,627 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-18 |
4 |
S |
$36.86 |
$1,028,407 |
D/D |
(27,852) |
8,517,293 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-18 |
4 |
S |
$36.56 |
$2,036,971 |
D/D |
(55,382) |
8,545,145 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-06-19 |
4 |
S |
$36.58 |
$3,658 |
D/D |
(100) |
8,600,227 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-02 |
4 |
S |
$38.33 |
$1,361,527 |
D/D |
(35,433) |
8,433,960 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-02 |
4 |
S |
$38.01 |
$1,831,020 |
D/D |
(47,900) |
8,469,393 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.37 |
$824,675 |
D/D |
(21,400) |
8,396,126 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.69 |
$1,611,552 |
D/D |
(41,496) |
8,354,630 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$37.99 |
$627,749 |
D/D |
(16,434) |
8,417,526 |
0 |
- |
|
PPDI |
Pharmaceutical Product De... |
CEO |
|
2007-07-16 |
4 |
S |
$38.99 |
$156,255 |
D/D |
(4,004) |
8,350,626 |
0 |
- |
|
148 Records found
|
|
Page 2 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|